Akintoye Emmanuel, Obaitan Itegbemie, Muthusamy Arunkumar, Akanbi Olalekan, Olusunmade Mayowa, Levine Diane
Emmanuel Akintoye, Arunkumar Muthusamy, Diane Levine, Department of Internal Medicine, Wayne State University School of Medicine/Detroit Medical Center, Detroit, MI 48201, United States.
World J Gastrointest Endosc. 2016 Aug 10;8(15):517-32. doi: 10.4253/wjge.v8.i15.517.
To systematically review the medical literature in order to evaluate the safety and efficacy of gastric endoscopic submucosal dissection (ESD).
We performed a comprehensive literature search of MEDLINE, Ovid, CINAHL, and Cochrane for studies reporting on the clinical efficacy and safety profile of gastric ESD.
Twenty-nine thousand five hundred and six tumors in 27155 patients (31% female) who underwent gastric ESD between 1999 and 2014 were included in this study. R0 resection rate was 90% (95%CI: 87%-92%) with significant between-study heterogeneity (P < 0.001) which was partly explained by difference in region (P = 0.02) and sample size (P = 0.04). Endoscopic en bloc and curative resection rates were 94% (95%CI: 93%-96%) and 86% (95%CI: 83%-89%) respectively. The rate of immediate and delayed perforation rates were 2.7% (95%CI: 2.1%-3.3%) and 0.39% (95%CI: 0.06%-2.4%) respectively while rates of immediate and delayed major bleeding were 2.9% (95%CI: 1.3-6.6) and 3.6% (95%CI: 3.1%-4.3%). After an average follow-up of about 30 mo post-operative, the rate of tumor recurrence was 0.02% (95%CI: 0.001-1.4) among those with R0 resection and 7.7% (95%CI: 3.6%-16%) among those without R0 resection. Overall, irrespective of the resection status, recurrence rate was 0.75% (95%CI: 0.42%-1.3%).
Our meta-analysis, the largest and most comprehensive assessment of gastric ESD till date, showed that gastric ESD is safe and effective for gastric tumors and warrants consideration as first line therapy when an expert operator is available.
系统回顾医学文献,以评估胃内镜黏膜下剥离术(ESD)的安全性和有效性。
我们对MEDLINE、Ovid、CINAHL和Cochrane进行了全面的文献检索,以查找报告胃ESD临床疗效和安全性的研究。
本研究纳入了1999年至2014年间接受胃ESD治疗的27155例患者(31%为女性)中的29506个肿瘤。R0切除率为90%(95%CI:87%-92%),研究间存在显著异质性(P<0.001),部分原因是地区差异(P=0.02)和样本量差异(P=0.04)。内镜整块切除率和根治性切除率分别为94%(95%CI:93%-96%)和86%(95%CI:83%-89%)。即刻穿孔率和延迟穿孔率分别为2.7%(95%CI:2.1%-3.3%)和0.39%(95%CI:0.06%-2.4%),即刻大出血率和延迟大出血率分别为2.9%(95%CI:1.3-6.6)和3.6%(95%CI:3.1%-4.3%)。术后平均随访约30个月,R0切除患者的肿瘤复发率为0.02%(95%CI:0.001-1.4),未行R0切除患者的复发率为7.7%(95%CI:3.6%-16%)。总体而言,无论切除状态如何,复发率为0.75%(95%CI:0.42%-1.3%)。
我们的荟萃分析是迄今为止对胃ESD最大规模、最全面的评估,表明胃ESD对胃肿瘤安全有效,在有经验的操作者可用时,值得作为一线治疗方法考虑。